AstraZeneca selects Clinigen for antibiotic access program
Clinigen has initiated an international global access program for AstraZeneca’s investigational antibiotic, CAZ-AVI (ceftazidame-avibactam).
CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming resistant to antibiotics.
The program is the first for Clinigen’s GAP (Global Access Program) with AstraZeneca and will provide access to CAZ-AVI to eligible patients worldwide with the exception of the US and Canada.
Healthcare Professionals will be able to request the drug for patients who have no other licensed therapeutic alternatives.
Shaun Chilton, COO of Clinigen, said in a statement: "We now work with AstraZeneca across all our operating businesses. The continued growth within Clinigen GAP demonstrates the increasing need for early access to drugs in areas of critical unmet need."
